Centrum Badan Klinicznych Pi-House Sp. z o.o. — Clinical Trial Site

119 Registered trials

41 Currently recruiting

Organisation

Centrum Badan Klinicznych Pi-House Sp. z o.o.

Location

Gdansk, Poland

Identifier

ORG-100040967

Address

Ul. Na Zaspe 3, 80-546, Poland

Departments

-
#5752: Dermatologia i Wenerologia
#7001; N/A
2656: Dermatologia i Wenerologia
40637: Dermatology
Centrum Badań Klinicznych PI-House
Centrum badan Klinicznych PI-House sp. z o.o
Centrum Badan Klinicznych Pi-House Sp. z o.o.
Centrum Badan Klinicznych PI-House sp. z o.o. Loc. 6
Centrum Badan Klinicznych PIHouse
Centrum Badan Klnicznych
Chronic pain
dermatology
Dermatology Department
N/A
NA
ND
No Department
not applicable
Private practice
Psychiatria
Psychiatry

Clinical trials at this site (119)

Search interface

A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Plaque Psoriasis 5 2026-04-28
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic… Recruiting

2025-522705-37-00 HIDRADENITIS SUPPURATIVA 4 2026-04-21
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Cold-Induced Urticaria and Symptomatic Dermographism 5 2026-04-13
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
DT-101 in Adults with Major Depressive Disorder Recruiting

2025-522784-15-00 Major Depressive Disorder 4 2026-03-24
A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting

2025-522642-44-00 CHRONIC SPONTANEOUS URTICARIA 4 2026-03-18
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on dise… Recruiting

2025-521684-12-00 Hidradenitis Suppurativa 4 2026-01-13
A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder. Recruiting

2025-522026-13-00 Obsessive compulsive disorder 4 2026-01-12
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting

2024-519836-18-00 treatment-resistant schizophrenia (TRS) 5 2025-12-16
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519418-29-00 Major Depressive Disorder 5 2025-09-19
A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting

2024-513171-41-00 Vitiligo 5 2025-09-11
A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Recruiting

2024-520328-27-00 Type 2 Diabetes 4 2025-08-07
A study to assess the efficacy and safety of ITI-1284 as monotherapy treatment in patients with Generalized Anxiety Disorder Recruiting

2024-516684-82-00 Generalized Anxiety Disorder 4 2025-07-21
A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacod… Recruiting

2024-517957-29-00 Mild Cognitive Impairment (MCI) 4 2025-04-02
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting

2023-504713-76-00 Dermatitis atopic 5 2024-12-03
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508539-30-00 Refractory Focal Onset Epilepsy 4 2024-10-10
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria… Recruiting

2022-500408-22-00 Plaque Psoriasis 5 2022-09-14
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU… Recruiting

2023-507372-42-00 Schizophrenia 4 2021-09-20
A Study of JNJ-95597528 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Ended

2025-523464-20-00 Moderate to Severe Atopic Dermatitis 4 2026-05-20